Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 16/20 | 0.69 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.68 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231754 | 0.89 | CXCR2 (0.67) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL5262356 | 0.86 | CXCR2 (0.63) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL5225672 | 0.84 | CXCR2 (0.70) | CXCR2CXCR1CX3CR1SMN1; SMN2RAB9A | |
| SCHEMBL4586744 | 0.83 | CXCR2 (0.81) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL1199477 | 0.82 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL6550665 | 0.81 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1HTTRAB9A | |
| SCHEMBL29372271 | 0.81 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL30515694 | 0.81 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL1535901 | 0.81 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL1199104 | 0.80 | CXCR2 (1.00) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261336-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2007-02-07 | — | — | EP | claimed |
| EP-1261336-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | claimed |
| US-6608077-B2 | Sulfonamide substituted diphenyl urea derivatives; treating chemokine mediated disease | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | claimed |
| US-20030055286-A1 | Sulfonamide substituted diphenyl urea derivatives; treating chemokine mediated disease | SMITHKLINE BEECHAM CORPORATION | 2003-03-20 | — | — | US | claimed |
| EP-1261336-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001068568-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-20 | — | — | WO | claimed |
| EP-1261336-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1261336-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6608077-B2 | Sulfonamide substituted diphenyl urea derivatives; treating chemokine mediated disease | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20030055286-A1 | Sulfonamide substituted diphenyl urea derivatives; treating chemokine mediated disease | SMITHKLINE BEECHAM CORPORATION | 2003-03-20 | — | — | US | disclosed |
| EP-1261336-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001068568-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055286-A1 | Sulfonamide substituted diphenyl urea derivatives; treating chemokine mediated disease | CXCL8, CCR8, CCL2 | CXCR2 10/4885CXCR1 5/4885CX3CR1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.